Financial Reporting - Sunshine Biopharma Inc. reported financial results for the period ended September 30, 2024[3] - The company issued a press release on November 6, 2024, detailing its financial performance[3] - The report is filed under Form 8-K, indicating compliance with SEC regulations[4] - The company is classified as an emerging growth company, which may affect its financial reporting standards[2] - The financial results include key metrics that will be elaborated in the attached press release[3] - The report does not incorporate any information that would subject the company to liability under the Exchange Act[4] - The financial statements and exhibits are included as part of the filing[5] - The report is not intended to be deemed "filed" under the Exchange Act[4] Company Information - Dr. Steve N. Slilaty serves as the Chief Executive Officer and signed the report[5] - The company is headquartered in Fort Lauderdale, FL[1]
Sunshine Biopharma(SBFM) - 2024 Q3 - Quarterly Results